



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 09/965,697  
Applicant : Dhadialla et al.  
Filed : September 27, 2001  
Art Unit : 1649  
Examiner : Michael T. Brannock  
Docket No. : A01115A-US  
Customer No. : 37978

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with applicant(s)' duty of disclosure under 37 C.F.R. § 1.56(a) and pursuant to 37 C.F.R. § 1.97 - 1.98, Applicants submit herewith copies of the documents listed on the enclosed Form, PTO-1449 "List of Art Cited by Applicant." Inclusion of a document in this Information Disclosure Statement is not intended to constitute an admission that any document so disclosed is "prior art" with respect to the present invention unless specifically so stated herein.

The filing of this Information Disclosure Statement shall not be construed to mean that a search has been made, or that no other material information, as defined in 37 C.F.R. § 1.56(a) exists.

The Examiner may find the enclosed documents relevant to the invention of the present application.

In accordance with 37 CFR §1.98(a)(2), a copy of each item listed on the enclosed Form, PTO-1449, is included herewith. Except where noted, each of the items listed are provided in the English language.

Respectfully submitted,

*Camille Jolly-Jornetta*  
Camille Jolly-Jornetta, Ph.D.  
Registration No. 48, 592

January 10, 2006

RheoGene, Inc.  
2650 Eisenhower Avenue  
Norristown, PA 19403



JAN 10 2006

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Substitute for form 1449/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(Use as many sheets as necessary)*

Sheet 1 of 2

**Complete if Known**

|                        |                  |
|------------------------|------------------|
| Application Number     | 09/965,697       |
| Filing Date            | 9/27/2001        |
| First Named Inventor   | Dhadialla        |
| Art Unit               | 1649             |
| Examiner Name          | Michael Brannock |
| Attorney Docket Number | A01115A          |

**U. S. PATENT DOCUMENTS**

## FOREIGN PATENT DOCUMENTS

|                       |  |                    |  |
|-----------------------|--|--------------------|--|
| Examiner<br>Signature |  | Date<br>Considered |  |
|-----------------------|--|--------------------|--|

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



JAN 10 2006

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

2

Application Number

09/965,697

Filing Date

9/27/2001

First Named Inventor

Dhadialla

Art Unit

1649

Examiner Name

Michael Brannock

Attorney Docket Number

A01115A

### NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|--------------------|-----------------------|---|----------------|
|                    |                       | ABLORDEPPEY et al., Is a Nitrogen Atom an Important Pharmacophoric Element in Sigma Ligand Binding? Bioorganic & Medicinal Chemistry (2000), 8(8), 2105-2111.   |                |
|                    |                       | NASSIF-MAKKI et al. Bisquaternary Ligands of the Common Allosteric Site of M2 Acetylcholine Receptors: Search for the Minimum Essential Distances between the Pharmacophoric Elements. Journal of Medicinal Chemistry (1999), 42(5), 849-858.                   |                |
|                    |                       | MALASKA et al. Chemical modification of ring C of himbacine: discovery of a Pharmacophoric Element for M2-selectivity. Bioorganic & Medicinal Chemistry Letters (1995), 5(1), 61-6.   |                |
|                    |                       | KOZIKOWSKI et al. Delineating the Pharmacophoric Elements of huperzine A: importance of the unsaturated three-carbon bridge to its AChE inhibitory activity. Journal of Medicinal Chemistry (1991), 34(12), 3399-402.   |                |
|                    |                       | BELSHAW et al. Rational design of orthogonal receptor-ligand combinations. Angewandte Chemie, International Edition in English (1995), 34(19), 2129-32.   |                |
|                    |                       | PIERCE et al. Computational binding studies of orthogonal cyclosporin-cyclophilin pairs. Angewandte Chemie, International Edition in English (1997), 36(13/14), 1466-1469.  |                |
|                    |                       | PEET et al. Engineering Novel Specificities for Ligand-Activated Transcription in the nuclear Hormone Receptor RXR. Chemistry & Biology, 1998, 5, 1, 13-21.   |                |
|                    |                       | HOLT et al. Functional Expression of Exogenous Proteins in Mammalian Sensory Hair Cells Infected with Adenoviral Vectors. J Neurophysiol. (1999), 81(4), 1881-8.  |                |
|                    |                       | DOYLE et al. Journal of the American Chemical Society (2001), 123(46), 11367-11371.   |                |
|                    |                       | Hoppe et al. Molecular Therapy (2000) 1(2), 159-164.  |                |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.